Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers

Modern Pathology

Volumn 23, Issue 2, 2010, Pages 276-283

  Yeh, Matthew M ^a   Daniel, Hubert Darius J ^b   Torbenson, Michael ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Non cirrhotic liver

Indexed keywords

AFLATOXIN; FORMALDEHYDE; PARAFFIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CODON; DISEASE ASSOCIATION; DISEASE COURSE; EXON; FEMALE; GENE MUTATION; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER FIBROSIS; MALE; MIXED INFECTION; PATIENT IDENTIFICATION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY; TERTIARY HEALTH CARE;

AGED; CARCINOMA, HEPATOCELLULAR; HEPATITIS C, CHRONIC; HUMANS; INFANT; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 76349089552     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.174     Document Type: Article

References (31)

1. El-Serag HB, Mason AC. Rising incidence of hepato-cellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
2. Buendia MA. Hepatitis B viruses and hepatocellular carcinoma. Adv Cancer Res 1992;59:167-226.
3. Wang XW, Forrester K, Yeh H, et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 1994;91: 2230-2234.
4. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepato-cellular carcinoma and death. Gut 2000;47:131-136.
5. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenter-ology 1997;112:463-472.
6. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687-1695.
7. Evert M, Dombrowski F. Hepatocellular carcinoma in the non-cirrhotic liver. Pathologe 2008;29:47-52.
8. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144: 705-714.
9. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002;2:479-486.
10. Katiyar S, Dash BC, Thakur V, et al. P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India. Cancer 2000;88:1565-1573.
11. Nzeako UC, Goodman ZD, Ishak KG. Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma. Cancer 1995;76:579-588.
12. Hamilton SR, Lauri A, (ed). WHO Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System. IARC Press: Lyon, 2000.
13. Greene FL, Page D, Fleming ID, et al (ed). AJCC Cancer Staging Handbook 6th edn. Springer-Verlag: New York, 2002.
14. Di Bisceglie AM, Lyra AC, Schwartz M, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003;98:2060-2063.
15. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005;25:143-154.
16. Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett 2007;252:157-170.
17. Kannangai R, Vivekanandan P, Netski D, et al. Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clin Virol 2007;39: 101-105.
18. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006;25:3834-3847.
19. Hsu HC, Jeng YM, Mao TL, et al. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000;157: 763-770.
20. Huang H, Fujii H, Sankila A, et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999;155:1795-1801.
21. Fukutomi T, Zhou Y, Kawai S, et al. Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology 2005;41:1096-1105.
22. Hussain SP, Schwank J, Staib F, et al. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007;26:2166-2176.
23. Hsu IC, Metcalf RA, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-428.
24. Scherzer TM, Reddy KR, Wrba F, et al. Hepatocellular carcinoma in long-term sustained virological respon-ders following antiviral combination therapy for chronic hepatitis C. J Viral Hepat 2008;15:659-665.
25. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35: 421-430.
26. Eguchi A, Nakashima O, Okudaira S, et al. Adenoma-tous hyperplasia in the vicinity of small hepatocellular carcinoma. Hepatology 1992;15:843-848.
27. Furuya K, Nakamura M, Yamamoto Y, et al. Macro-regenerative nodule of the liver. A clinicopathologic study of 345 autopsy cases of chronic liver disease. Cancer 1988;61:99-105.
28. Takayama T, Makuuchi M, Hirohashi S, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990;336: 1150-1153.
29. Terada T, Ueda K, Nakanuma Y. Histopathological and morphometric analysis of atypical adenomatous hy-perplasia of human cirrhotic livers. Virchows Arch A Pathol Anat Histopathol 1993;422:381-388.
30. Hytiroglou P, Park YN, Krinsky G, et al. Hepatic precancerous lesions and small hepatocellular carcinoma. Gastroenterol Clin North Am 2007;36: 867-887, vii.
31. Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 2005;25:16-27.